NASDAQ:ABCL
AbCellera Biologics Inc.
AbCellera Biologics Inc.'s revenue grew 160.6% in fiscal 2025 to $75.1M while operating margin rose to −289.0%. Free cash flow was −$174.1M, −231.7% of revenue, and the diluted share count rose 1.5%.Summary generated from AbCellera Biologics Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$75.1M
Revenue growth+160.6%
Revenue, 5-yr CAGR−20.3%
Gross marginn/a
Operating margin−289.0%
Net margin−194.9%
ROICn/a
Return on equity−14.5%
Debt / equityn/a
Free cash flow−$174.1M
FCF margin−231.7%
Share count change+1.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 375 | 485 | 38 | 29 | 75 |
| Operating income | 204 | 217 | −237 | −315 | −217 |
| Net income | 153 | 159 | −146 | −163 | −146 |
| Free cash flow | 186 | 207 | −121 | −187 | −174 |
Recent filings
- 4Insider transaction report
Aug 24, 2026 - 4Insider transaction report
Aug 18, 2026 - 8-KEntry into a material agreement
Aug 13, 2026 - 8-KRegulation FD disclosure
Aug 10, 2026 - 8-KOther events
Aug 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KOther events
Jul 29, 2026